{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T07:41:01Z","timestamp":1788594061772,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T00:00:00Z","timestamp":1777334400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtct.2026.04.032","type":"journal-article","created":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T15:14:53Z","timestamp":1777130093000},"page":"1086-1097","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7341-5205","authenticated-orcid":false,"given":"Amrita","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8694-9174","authenticated-orcid":false,"given":"Cristian D.","family":"Valenzuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-1645-3089","authenticated-orcid":false,"given":"Kevin","family":"Christmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise","family":"Lackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Trussell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4380-4573","authenticated-orcid":false,"given":"Brandon","family":"Hayes-Lattin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabrielle","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Blackburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl","family":"Stomberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bashi","family":"Ratterree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Bixler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1356-3250","authenticated-orcid":false,"given":"Rebekah","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staci","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Vetto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8184-7099","authenticated-orcid":false,"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2026.04.032_bib0001","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.3489291","article-title":"A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes","volume":"233","author":"Rosenberg","year":"1986","journal-title":"Science"},{"issue":"25","key":"10.1016\/j.jtct.2026.04.032_bib0002","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.jtct.2026.04.032_bib0003","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0004","series-title":"SITC 37th Annual Meeting (SITC 2022) Abstracts","article-title":"Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapy: pooled analysis of consecutive cohorts (C-144-01 study)","author":"Sarnaik","year":"2022"},{"key":"10.1016\/j.jtct.2026.04.032_bib0005","first-page":"141","article-title":"What to do when anti-PD-1 therapy fails in patients with melanoma","volume":"33","author":"Mooradian","year":"2019","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jtct.2026.04.032_bib0006","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1158\/1078-0432.CCR-17-2267","article-title":"Primary and acquired resistance to immune checkpoint inhibitors in metastatic melanoma","volume":"24","author":"Gide","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2026.04.032_bib0007","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.032_bib0008","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.032_bib0009","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1093\/annonc\/mdz011","article-title":"Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001","volume":"30","author":"Hamid","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0010","doi-asserted-by":"crossref","first-page":"4576","DOI":"10.3390\/ijms21134576","article-title":"Targeted therapy in melanoma and mechanisms of resistance","volume":"21","author":"Czarnecka","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtct.2026.04.032_bib0011","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1093\/annonc\/mdx176","article-title":"Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E\/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study","volume":"28","author":"Long","year":"2017","journal-title":"Ann Oncol"},{"issue":"suppl","key":"10.1016\/j.jtct.2026.04.032_bib0012","article-title":"The utility of chemotherapy after immunotherapy failure in metastatic melanoma: A multicenter case series","volume":"36","author":"Goldinger","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0013","article-title":"Salvage therapy after failure from anti-PD-1 single agent treatment: A study by the German ADOReg melanoma registry","volume":"37","author":"Weichenthal","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0014","doi-asserted-by":"crossref","first-page":"S171","DOI":"10.1016\/j.jcyt.2025.03.346","article-title":"Real world experience of a single-center tumor infiltrating lymphocyte (til) melanoma therapy program: primary referral to TIL infusion (brain to vein)","volume":"27","author":"Desai","year":"2025","journal-title":"Cytotherapy"},{"issue":"12","key":"10.1016\/j.jtct.2026.04.032_bib0015","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.04.032_bib0016","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0017","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy, or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2026.04.032_bib0018","series-title":"Paper presented at: ESMO Congress","article-title":"Treatment with tumor-infiltrating lymphocytes (TIL) versus ipilimumab for advanced melanoma: results from a multicenter, randomized phase trial","author":"Haanen","year":"2022"},{"key":"10.1016\/j.jtct.2026.04.032_bib0019","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1158\/1078-0432.CCR-21-4499","article-title":"Neoantigen identification and response to adoptive cell transfer in anti-PD-1 na\u00efve and experienced patients with metastatic melanoma","volume":"28","author":"Levi","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.jtct.2026.04.032_bib0020","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jtct.2026.04.032_bib0021","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1497522","article-title":"Tumor-infiltrating lymphocytes in melanoma: from prognostic assessment to therapeutic applications","volume":"15","author":"Bida","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0022","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/bjc.2017.220","article-title":"HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer","volume":"117","author":"Barnes","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtct.2026.04.032_bib0023","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S1470-2045(01)00620-9","article-title":"Melanoma\u2013stroma interactions: structural and functional aspects","volume":"3","author":"Ruiter","year":"2002","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2026.04.032_bib0024","first-page":"A523","article-title":"492 Phase 2 efficacy and safety of autologous tumor-infiltrating lymphocyte (TIL) cell therapy in combination with pembrolizumab in immune checkpoint inhibitor na\u00efve patients with advanced cancers","volume":"9","author":"O\u2019Malley","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.04.032_bib0025","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1126\/science.aaa6204","article-title":"T cell exclusion, immune privilege, and the tumor microenvironment","volume":"348","author":"Joyce","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jtct.2026.04.032_bib0026","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.trecan.2017.09.006","article-title":"Migrating into the tumor: a roadmap for T cells","volume":"3","author":"Van Der Woude","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.jtct.2026.04.032_bib0027","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","article-title":"The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition","volume":"22","author":"Hegde","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.jtct.2026.04.032_bib0028","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40425-014-0026-0","article-title":"High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014","volume":"2","author":"Dutcher","year":"2014","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jtct.2026.04.032_bib0029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008735","article-title":"Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy","volume":"12","author":"Betof Warner","year":"2024","journal-title":"J Immunother Cancer"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636726003192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T19:58:14Z","timestamp":1788551894000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636726003192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":29,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2666636726003192"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.032","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Clinical Outcomes in Melanoma Patients Treated at a Single-Center Tumor Infiltrating Lymphocyte (TIL) Therapy Program Using Commercial Lifileucel","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2026.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}